Jung HJ, Coleman R, Woodward OM et al (2021) Doxycycline Changes the Transcriptome Profile of mIMCD3 Renal Epithelial Cells. Frontiers in Physiology Renal and Epithelial Physiology. Nov 5;12:771691. doi: 10.3389/fphys.2021.771691. PMCID: PMC8602682
Cordido A, Nuñez-Gonzalez L, Martinez-Moreno JM, et al. TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease J Am Soc Nephrol. 2021 Aug;32(8):1913-1932. doi: 10.1681/ASN.2020071094. Epub 2021 Jun 21. PMID: 34155062
Aloria EJG, Song CJ, Li et al. Ly6chi Infiltrating Macrophages Promote Cyst Progression in Injured Conditional Ift88 Mice. Kidney 360 24: 989-95, 2021.
Senum SR, Li YSM, Benson KA, Joli G, Olinger E, Lavu S, Madsen CD, Gregory AV, Neatu R, Kline TL, Audrézet MP, Outeda P, Nau CB, Meijer E, Ali H, Steinman TI, Mrug M, Phelan PJ, Watnick TJ, Peters DJM, Ong ACM, Conlon PJ, Perrone RD, Cornec-Le Gall E, Hogan MC, Torres VE, Sayer JA; Genomics England Research Consortium, the HALT PKD, CRISP, DIPAK, ADPKD Modifier, and TAME PKD studies, Harris PC. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet. 2022 Jan 6;109(1):136-156. doi: 10.1016/j.ajhg.2021.11.016. Epub 2021 Dec 9. PMID: 34890546
Perrone RD, Abebe KZ, Watnick TJ, Althouse AD, Hallows KR, Lalama CM, Miskulin DC, Seliger SL, Tao C, Harris PC, Bae KT. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int. 2021 Sep;100(3):684-696. doi: 10.1016/j.kint.2021.06.013. Epub 2021 Jun 27. PMID: 34186056.
Yao Q, Outeda P, Xu H, Walker R, Basquin D, Qian F, Cebotaru L, Watnick T, Cebotaru V. Polycystin-1 dependent regulation of polycystin-2 via GRP94, a member of HSP90 family that resides in the endoplasmic reticulum. FASEB J. 2021 Oct;35(10):e21865. doi: 10.1096/fj.202100325RR. PMID: 34486178
Yanda MK, Tomar V, Cole R et al. The Mitochondrial Ca2+ import complex is altered in ADPKD. Cell Calcium. 2022 Jan;101:102501. doi: 10.1016/j.ceca.2021.102501. Epub 2021 Nov 19.PMID: 34823104
Jamadar A, Suma SM, Mathew S et al. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death Dis. 2021 Oct 14;12(10):947. PMID: 34650051.
El Ters M, Lu P, Mahnken JD et al. Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2021 Jan 16;6(4):953-961. doi: 10.1016/j.ekir.2021.01.004. PMID: 33912745.
Radadiya PS, Thornton MM, Daniel EA et al. Quinomycin A reduces cyst progression in polycystic kidney disease. FASEB J. 2021 May;35(5):e21533. doi: 10.1096/fj.202002490R. PMID: 33826787.
Radadiya PS, Thornton MM, Puri RV et al. Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease. JCI Insight. 2021 Mar 30;6(8):e141299. doi: 10.1172/jci.insight.141299.PMID: 33784251